Find company announcements below, or check out the latest news in the right side menu.
21. January 2013
Organic sales growth was 4% (7% DKK, 3% LCY) compared with 2011. EBIT increased by 17%, raising the EBIT margin to 24.4%. Net profit grew by 10%. Strong free cash flow before acquisitions of DKK 1,581 million exceeded the outlook.
7. January 2013
9. November 2012
In accordance with section 29 of the Danish Securities Trading Act, Novozymes has been informed that Baillie Gifford & Co, together with its wholly owned subsidiary Baillie Gifford Overseas Ltd, has decreased its holding of B shares in Novozymes to 7.56%
6. November 2012
In reference to company announcement no. 68 of October 29 2012, the closing conditions for the transaction have been met, and the transaction between Novozymes and Beta Renewables has now been closed. Following the transaction, Novozymes’ share of ownership of Beta Renewables is 9.95%.
29. October 2012
Companies enter into strategic partnership making Novozymes the preferred enzyme supplier for Beta Renewables’ current and future cellulosic biofuel projects.
With the announcement today of the strategic partnership with and acquisition of a share in Beta Renewables (Company announcement No. 68), the aforementioned share buyback program is hereby terminated.
26. October 2012
On January 20, 2012, Novozymes initiated a share buyback program in accordance with the provisions of European Commission Regulation no. 2273/2003 of December 22, 2003, also referred to as the Safe Harbour Regulation.
25. October 2012
Sales growth in DKK was 6% (2% LCY, 3% organic) compared with the first 9 months of 2011. EBIT grew by 12%, and the EBIT margin increased to 24.6%. The expectations for full-year 2012 EBIT growth, EBIT margin and net profit growth are maintained, as is the expectation for free cash flow.
19. October 2012
12. October 2012
5. October 2012
28. September 2012
21. September 2012
14. September 2012
12. September 2012
Baillie Gifford & Co, together with its wholly owned subsidiary Baillie Gifford Overseas Limited, has decreased its holding of B shares in Novozymes to 7.64%, previously reported at 7.82% (a decrease of 0.18%).
7. September 2012
31. August 2012
24. August 2012
17. August 2012
16. August 2012
Sales growth in DKK was 7% (3% LCY, 3% organic) compared with the first half of 2011. EBIT grew by 12%, and the EBIT margin increased to 24.2%. The expectation for full-year 2012 EBIT growth is increased to 11-14% from 9-12%, and EBIT margin is now expected at 23-24%.
10. August 2012
3. August 2012
27. July 2012
Baillie Gifford & Co, together with its wholly owned subsidiary Baillie Gifford Overseas Limited, has increased its holding of B shares in Novozymes to 7.82%, previously reported at 7.71% (an increase of 0.11%).
4. December 2013
27. November 2013
| Copyright © 2013 Novozymes. All Rights Reserved.